Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Can Abbisko Therapeutics turn irpagratinib into the first approved FGFR4 therapy for hepatocellular carcinoma?

Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.

Read More
Representative image of prescription eye drops and reading glasses, illustrating how Tenpoint Therapeutics and PHIL are using a direct-to-patient YUVEZZI access program to improve affordability and expand presbyopia treatment access.
Pharma & Biotech

Can Tenpoint Therapeutics’ direct-to-patient YUVEZZI program unlock wider access in the presbyopia market?

Tenpoint Therapeutics and PHIL launch YUVEZZI direct-to-patient access for presbyopia. Read what it means for affordability, uptake, and market adoption.

Read More
Pharma & Biotech

PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen

PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.

Read More
Pharma & Biotech

Why CTIS is betting FDA’s E2B(R3) deadline will reshape pharmacovigilance software demand;

CTIS launches Trial SafetyXchange to help pharma firms meet the FDA E2B(R3) deadline. Read what it changes for safety reporting teams.

Read More
Pharma & Biotech

Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?

Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected

Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.

Read More
Representative image of a patient using a digital mental health app during a teletherapy consultation, reflecting how Syra Health and Nora Mental Health are linking AI-driven triage with licensed behavioral care in Indiana.
Pharma & Biotech

Why the Syra Health and Nora Mental Health deal matters for telebehavioral care in Indiana

Syra Health and Nora Mental Health are linking AI triage with teletherapy in Indiana. Read why this could reshape digital mental health access.

Read More
Representative image of idiopathic pulmonary fibrosis treatment and specialty respiratory care, illustrating why Cipla’s U.S. nintedanib approval could reshape access, pricing, and competition in the pulmonary fibrosis drug market.
Pharma & Biotech

Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market

Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.

Read More
Pharma & Biotech

Why SV Health Investors’ EpiVax acquisition signals a bigger private equity push into immunogenicity services

SV Health Investors acquires EpiVax. Read why immunogenicity risk assessment is becoming a more strategic pharma services market.

Read More
Representative image of microbiome therapeutics research as Vedanta Biosciences advances VE303 in Phase 3 for recurrent Clostridioides difficile infection, highlighting the growing stakes in standardized live biotherapeutic development.
Pharma & Biotech

Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar

Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.

Read More